Abstract 5323
Background
In terminal cancer patients with a limited prognosis, excessive radiotherapy (RT) fractionation can be considered an avoidable harm and poor use of healthcare resource. 30-day mortality (30DM) as a clinical indicator for the avoidance of harm, through appropriate patient selection, in palliative RT has not previously been demonstrated in Hong Kong. We aimed to assess 30DM following palliative RT at our centre.
Methods
A retrospective analysis of 30DM for all palliative RT delivered in Tuen Mun Hospital in 2017. Episodes were identified using the in-house radiotherapy electronic record with linkage to electronic patient records. 30DM was assessed across all patient groups and by sites and fractionation pattern.
Results
1,065 palliative RT episodes were identified. Overall, 199 (18.7%) treatment were delivered to the spine, 151 (14.2%) to the chest, 97 (9.1%) to the brain, and 77 (7.2%) to the bones. Median treatment duration was 5 days (range 1–12). 84.3% received 5 fractions or less. Overall 30DM was 17.7% (188 patients), among which 61 (32.4%) treatment episodes were delivered to female. The most commonly treated diagnosis was lung cancer (39.4%). Factors having a significant impact upon 30DM were sex (male vs female odds ratio [OR] 1.56, 95% confidence interval [CI] 1.12, 2.18) and primary cancer diagnosis (Lip, oral cavity, and pharynx OR 0.31 [0.11, 0.87], genitourinary organs OR 0.57 [0.33, 0.98], and respiratory and intrathoracic organs 1.60 [1.17, 2.20]).Table:
1602P odd ratios for different factors relating to the 30DM of palliative RT
Yes (mortality within 30 days) | No | ||
---|---|---|---|
Total n = 1065 | No. of Cases (%) | No. of Cases (%) | Odd ratios (95% CI) |
Radiotherapy Sites | |||
Lip, oral cavity, and pharynx | 4 (7) | 57 (93) | 0.31 (0.11, 0.87) |
Genitourinary organs | 16 (11) | 124 (89) | 0.57 (0.33, 0.98) |
Bone, connective tissue, skin and breast | 23 (14) | 144 (86) | 0.71 (0.44, 1.14) |
Other and unspecified sites | 8 (17) | 40 (83) | 0.93 (0.43, 2.02) |
Digestive organs and peritoneum | 35 (18) | 159 (82) | 1.03 (0.69, 1.55) |
Respiratory and intrathoracic organs | 92 (22) | 328 (78) | 1.60 (1.17, 2.20) |
Lymphatic and hematopoietic Tissue | 10 (29) | 25 (71) | 1.92 (0.90, 4.06) |
Sex | |||
Male | 127 (20) | 501 (80) | 1.56 (1.12, 2.18) |
Female | 61 (14) | 376 (86) |
Abbreviation: CI: confidence interval
Conclusions
This is the first large-scale study of 30-day mortality for unselected adult palliative RT in Hong Kong. A balance needs to be achieved between duration of RT course and potential benefits through appropriate patient selection. The observed differences in early mortality by fractionation support the use of this measure in assessing clinical decision making in palliative RT, and further studies in other centres and health care systems are required.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Shing Fung Lee.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5437 - Salivary cytokines and oral mucosa cells apoptosis in patients during hematopoietic cell transplantation: possible relationship with oral mucositis
Presenter: Luciana Corrêa
Session: Poster Display session 1
Resources:
Abstract
1483 - A randomized trial of sodium alginate prevention of radiation-induced esophagitis in patients with locally advanced NSCLC receiving concurrent chemoradiotherapy: OLCSG1401
Presenter: Toshihide Yokoyama
Session: Poster Display session 1
Resources:
Abstract
2047 - Taste and smell alterations (TSAs) in patients (pts) with stage II-III colon cancer (CC): a pilot within the PROTECT study
Presenter: Jeroen Derksen
Session: Poster Display session 1
Resources:
Abstract
5984 - Clinical characteristics are associated with acupuncture treatment response for xerostomia in cancer patients
Presenter: Wenli Liu
Session: Poster Display session 1
Resources:
Abstract
2845 - Psychosocial Distress of Adolescent and Young Adults with Cancer at Diagnosis: A Case-Matched Retrospective Cohort of 2045 Patients in British Columbia.
Presenter: Alannah Smrke
Session: Poster Display session 1
Resources:
Abstract
724 - Accuracy of distress thermometer to measure cancer-related mood disorders in Chinese patients with cancer
Presenter: Sudip Thapa
Session: Poster Display session 1
Resources:
Abstract
2357 - Modalities of biosimilar filgrastim use in clinical practice in >1000 patients receiving chemotherapy regimens with a rest period of ≤14 days: the TOPAZE study
Presenter: Jean Marc Phelip
Session: Poster Display session 1
Resources:
Abstract
1426 - The Effect of Increasing Doses of Pegfilgrastim (Peg) on Thrombocytopenia (T) in Breast Cancer (BC) Patients (pts) Receiving Taxotere (Doc), Doxorubicin, Cyclophosphamide (TAC) and Plinabulin (Plin)
Presenter: Douglas Blayney
Session: Poster Display session 1
Resources:
Abstract
712 - The use of intravenous ferric carboxymaltose without erythropoiesis-stimulating agents in the treatment of anemia in cancer patients undergoing chemotherapy with or without radiotherapy
Presenter: Hikmat Abdel-Razeq
Session: Poster Display session 1
Resources:
Abstract
1496 - Randomized, double-blind, cross-over Phase I study comparing pharmacokinetics, pharmacodynamics, safety and immunogenicity of a biosimilar pegfilgrastim with EU and US references
Presenter: Maria Velinova
Session: Poster Display session 1
Resources:
Abstract